Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy

Human epidermal growth factor receptor 2 (HER2)–positive breast cancers are currently treated with trastuzumab, an anti-HER2 antibody. About 30% of these tumors express a group of HER2 fragments collectively known as p95HER2. Our previous work indicated that p95HER2-positive tumors are resistant to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Natl Cancer Inst
Autores principales: Parra-Palau, Josep Lluís, Morancho, Beatriz, Peg, Vicente, Escorihuela, Marta, Scaltriti, Maurizio, Vicario, Rocio, Zacarias-Fluck, Mariano, Pedersen, Kim, Pandiella, Atanasio, Nuciforo, Paolo, Serra, Violeta, Cortés, Javier, Baselga, José, Perou, Charles M., Prat, Aleix, Rubio, Isabel T., Arribas, Joaquín
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2014
Materias:
Brief Communication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4271027/
https://ncbi.nlm.nih.gov/pubmed/25253614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju291
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares